Is the ₹9,000 Cr Power 930 target still achievable after FY26 base of ~₹900 Cr, implying a 10x jump in 4 years?

Dr. SRN explained that the design-to-manufacturing transition automatically provides a 10x–20x scale-up. The company is moving from being an 'architect' (3% of value) to a 'builder' (97% of value). He reiterated the target is not scaled down and momentum will accelerate from FY27 as facilities become operational.

After adjusting for revenue deferment, normalized EBITDA margins are ~17%. Can FY27 margins reach 20% based on prior 300 bps improvement indication?

Shashi stated that the divested non-core verticals were margin dilutive; the retained core verticals already have ~20%+ EBITDA margins. He guided for an incremental 150–200 bps improvement on this base in FY27. Dr. SRN added context on large program pipeline.

How is the Akkodis deal structured? Will AXISCADES continue to run the business until the earnout?

Shashi clarified it is a slump sale. The guaranteed portion is $23.4 million, with 75% paid on closing and 25% after one year; an additional earnout of up to $7.4 million is tied to FY27 EBITDA targets. AXISCADES will handhold for one year post-transfer, but the business will be managed by Akkodis.

How will the large capex program (₹1,100–1,200 Cr) and acquisitions be funded given negative cash flow and increased short-term borrowings?

Dr. SRN disclosed that Phase 2 divestment will be much larger and will fund the entire capex and acquisition plan. Mukund confirmed no equity dilution and no incremental long-term debt, only working capital and bridge financing.

What are the specifics of the new space and hyperscaler strategies, and when will revenue start?

Dr. SRN detailed Xida Inc. (US-based deep tech/AI) targeting data centers, test rigs, and semiconductor customers, with a 10x revenue possibility. Space focuses on bus, payload, and SAR manufacturing. He expected more clarity on both in 30–45 days and invited investors to an open house.

To reach ₹9,000 Cr by FY30, a 90% CAGR is needed from FY28–FY30. Will this growth start from FY28? Also, will PAT significantly exceed the ₹960 Cr target?

Dr. SRN avoided committing to a specific CAGR but said the architect-to-builder transition and acquisitions will drive scale. He stated that the ₹960 Cr PAT target could be achieved much earlier than FY30 with ₹7,200 Cr revenue, and margins may stabilize at 25–27%.

What is the plan for ESOPs in FY27, given the ₹5 Cr provision discussed last quarter?

Dr. SRN said the entire 3.8 million share ESOP pool will be awarded by Q2FY27, aligned with the restructuring and Akkodis income. The headcount will reduce from 2,800 to 1,200 post-restructuring, allowing recalibration of ESOP allocation.

What is the detailed capex and capital allocation plan after the Akkodis proceeds?

Dr. SRN broke down the organic capex for three facilities at ~₹1,550–1,600 Cr and acquisitions at ~₹600 Cr (2 ESAI, 2 aerospace), totaling ₹2,100–2,250 Cr. He stated Phase 1 and Phase 2 divestments together will fund ~80% of this, with the remainder from internal accruals or partnerships.

AXISCADES Tech. Q4 FY26 Earnings Call — Analysis (NSE: AXISCADES)

AXISCADES Q4 PAT drops 98% YoY to ₹0.42 Cr as ₹142 Cr revenue deferment and restructuring costs hit reported numbers, but management frames FY26 as a transformative 'building year' and reaffirms the ₹9,000 Cr Power 930 ambition.

18 Jun 2026 · Analysis by Alpha Inflection

The take

FY26 Revenue ₹1,159 Cr ( +12.4% YoY ) . New guidance — FY2030 revenue target ₹9,000 Cr . New story: Portfolio sharpening to core A&D and deep tech .

Results

Q4FY26 revenue ₹273 Cr, EBITDA ₹34 Cr, PAT ₹0.42 Cr; full-year FY26 revenue ₹1,159 Cr +12.4% YoY, EBITDA ₹178 Cr +24.6% YoY, EBITDA margin 15.3% (+150 bps), reported PAT ₹72 Cr (-4.3% YoY) impacted by Q4 deferment and exceptional items.

Financial highlights

AXISCADES Tech. Q4 FY26 reported figures
Metric	Value	Change	Basis
FY26 Revenue	₹1,159 Cr	+12.4%	yoy · FY26
FY26 EBITDA	₹178 Cr	+24.6%	yoy · FY26
FY26 EBITDA Margin	15.3%	+150 bps	yoy · FY26
FY26 Reported PAT	₹72 Cr	-4.3%	yoy · FY26
Q4 Revenue	₹273 Cr		point_in_time · Q4FY26 · Q4FY26
Q4 EBITDA	₹34 Cr		point_in_time · Q4FY26 · Q4FY26
Q4 PAT	₹0.42 Cr		point_in_time · Q4FY26 · Q4FY26
Revenue Deferment	₹142 Cr		point_in_time · Q4FY26 · Q4FY26
Order Book Under Execution	₹927 Cr		point_in_time · FY27 · as of May 30, 2026
Receivables	₹411 Cr		point_in_time · FY26 end · Mar-26
DSO	130 days		point_in_time · FY26 end · Mar-26

Guidance

FY27 revenue trending towards ₹1,377 Cr (52% growth on retained base), with deferred ₹142 Cr to be recognized in Q1-Q2; core EBITDA margin expected to improve 150-200 bps; extraordinary gain of ~₹175 Cr on Akkodis divestment closure in Q2FY27.

What management committed to

AXISCADES targets ₹9,000 Cr revenue by FY2030 under the Power 930 roadmap. — ₹9,000 Cr, FY2030
AXISCADES will achieve PAT of ₹960 Cr by FY2030 or earlier, potentially with only ₹7,200 Cr revenue. — ₹960 Cr, FY2030
Phase 2 of the disinvestment will be completed in H1 FY27. — Q2FY27
An aerospace manufacturing acquisition will be finalized and jumpstart high-value manufacturing in Q3 FY27. — Q3FY27
Xida Inc. will have 3 to 4 more large customers by the end of FY27. — 3 to 4, FY27
The deferred revenue of ₹142 Cr from Q4FY26 will be recognized in Q1 and Q2 FY27. — ₹142 Cr, Q2FY27
Consolidated FY27 revenue is trending towards ₹1,377 Cr. — ₹1,377 Cr, FY27
Core business EBITDA margin will improve by 150–200 bps year-on-year in FY27. — 150–200 bps, FY27
Extraordinary gain of approximately ₹175 Cr will be realized on closure of the Akkodis divestment, expected in Q2 FY27. — ₹175 Cr, Q2FY27
AXISCADES will not undertake equity dilution or any incremental long-term debt; only working capital debt and short-term bridge financing will be used.
The entire 3.8 million share ESOP pool will be awarded by Q2 FY27. — 3.8 million shares, Q2FY27
Contracts with two major OEMs will be completed by Q3 FY27. — Q3FY27

Key themes

Portfolio sharpening and manufacturing transition

How the narrative shifted

Portfolio sharpening to core A&D and deep tech: Management is divesting non-core engineering services to concentrate capital and bandwidth on aerospace, defense, space, and deep tech AI, which have structurally higher margins and longer lifecycles.
Design-to-manufacturing transition for scale: Moving from design-only services to manufacturing and solutions is positioned as the key to unlocking 10x revenue, analogous to an architect becoming a builder and capturing the full value chain.
Supply chain and execution volatility: Q4 revenue deferment is attributed to global supply chain disruptions and a supplier redirecting output to war-related programs; management frames it as a scheduling issue, not demand erosion, and commits to building supply chain buffers.
Global OEM and customer acquisition: AXISCADES is aggressively expanding its relationship with global OEMs, hyperscalers, and semiconductor companies (Qualcomm, large consumer tech) through a US-incorporated subsidiary (Xida) and Vietnam-based acquisitions to access near-shore capabilities.
Capex and infrastructure build-out: Three major manufacturing facilities (DAL, DAC, MAC) are becoming operational through FY27, with a combined organic capex of ~₹1,600 Cr, intended to provide the physical capacity for the manufacturing transition.
Working capital and cash flow normalization: Elevated year-end receivables (DSO 130 days) and negative operating cash flow are presented as a temporary result of program execution timing (land systems WIP), with ₹154 Cr already collected post-March and a return to normal pattern expected in H1FY27.
Acquisition-led growth acceleration: Inorganic acquisitions in aerospace manufacturing and ESAI are positioned as a tool to buy time, acquire certifications, customer relationships, and manufacturing skills, directly contributing to FY27 revenue visibility and the Power 930 goal.

Operational commentary

Signed definitive agreement to divest heavy engineering, energy, and automotive engineering services practice to Akkodis for $30.63 million cash pre-tax; expected to close in Q2FY27 with an extraordinary gain of ~₹175 Cr.
Power 930 roadmap maintained: ₹9,000 Cr revenue target by FY2030, with design-to-manufacturing transition as the core growth lever.
DAL, DAC, and MAC manufacturing facilities to become operational through FY27; Devanahalli campuses and Hyderabad MAC to enable large-scale manufacturing and MRO.
Advanced stages of finalizing an aerospace manufacturing acquisition to jumpstart high-value manufacturing in Q3FY27.
Establishment of Xida Inc., a US-incorporated (Silicon Valley) deep tech and AI subsidiary, housing existing ESAI business, targeting data centers, generative AI, and physical AI; two acquisitions under evaluation.
Space division operational; space situational awareness initiative with Aldoria underway; evaluating strategic partnerships for space bus and payload manufacturing at Devanahalli.
21 design wins in defense; shortlisted for large programs (swarm drones, CLRTS, HAL) among 3-5 contenders; potential to catapult into major league.
Qualcomm order of $3.5 million secured in 2-3 months; pipeline of $0.5–1 million monthly run rate indicated; hyperscaler and large consumer tech company engagements advancing.
Q4FY26 revenue deferment of ₹142 Cr due to supply chain disruptions (defense manufacturing, strategic electronics, Akkodis transition); orders intact, recognition shifted to Q1-Q2FY27.
Phase 2 of disinvestment on track for H1FY27; expected to fund the majority of capex (₹1,550–1,600 Cr) and acquisitions (₹600 Cr) without equity dilution or long-term debt.
ESOP pool of 3.8 million shares to be awarded by Q2FY27, aligned with restructuring completion and extraordinary income from Akkodis deal.
OEM partnerships progressing; contracts with two major OEMs expected to be completed by Q3FY27, subject to Government of India approvals.
Post-collection, receivables DSO normalized to 81 days; operating cash flow deficit in FY26 attributed to land systems WIP and revenue deferment, with ₹120–140 Cr cash release expected in H1FY27.

Analyst Q&A

Q. Is the ₹9,000 Cr Power 930 target still achievable after FY26 base of ~₹900 Cr, implying a 10x jump in 4 years?
Dr. SRN explained that the design-to-manufacturing transition automatically provides a 10x–20x scale-up. The company is moving from being an 'architect' (3% of value) to a 'builder' (97% of value). He reiterated the target is not scaled down and momentum will accelerate from FY27 as facilities become operational.
Q. After adjusting for revenue deferment, normalized EBITDA margins are ~17%. Can FY27 margins reach 20% based on prior 300 bps improvement indication?
Shashi stated that the divested non-core verticals were margin dilutive; the retained core verticals already have ~20%+ EBITDA margins. He guided for an incremental 150–200 bps improvement on this base in FY27. Dr. SRN added context on large program pipeline.
Q. How is the Akkodis deal structured? Will AXISCADES continue to run the business until the earnout?
Shashi clarified it is a slump sale. The guaranteed portion is $23.4 million, with 75% paid on closing and 25% after one year; an additional earnout of up to $7.4 million is tied to FY27 EBITDA targets. AXISCADES will handhold for one year post-transfer, but the business will be managed by Akkodis.
Q. How will the large capex program (₹1,100–1,200 Cr) and acquisitions be funded given negative cash flow and increased short-term borrowings?
Dr. SRN disclosed that Phase 2 divestment will be much larger and will fund the entire capex and acquisition plan. Mukund confirmed no equity dilution and no incremental long-term debt, only working capital and bridge financing.
Q. What are the specifics of the new space and hyperscaler strategies, and when will revenue start?
Dr. SRN detailed Xida Inc. (US-based deep tech/AI) targeting data centers, test rigs, and semiconductor customers, with a 10x revenue possibility. Space focuses on bus, payload, and SAR manufacturing. He expected more clarity on both in 30–45 days and invited investors to an open house.
Q. To reach ₹9,000 Cr by FY30, a 90% CAGR is needed from FY28–FY30. Will this growth start from FY28? Also, will PAT significantly exceed the ₹960 Cr target?
Dr. SRN avoided committing to a specific CAGR but said the architect-to-builder transition and acquisitions will drive scale. He stated that the ₹960 Cr PAT target could be achieved much earlier than FY30 with ₹7,200 Cr revenue, and margins may stabilize at 25–27%.
Q. What is the plan for ESOPs in FY27, given the ₹5 Cr provision discussed last quarter?
Dr. SRN said the entire 3.8 million share ESOP pool will be awarded by Q2FY27, aligned with the restructuring and Akkodis income. The headcount will reduce from 2,800 to 1,200 post-restructuring, allowing recalibration of ESOP allocation.
Q. What is the detailed capex and capital allocation plan after the Akkodis proceeds?
Dr. SRN broke down the organic capex for three facilities at ~₹1,550–1,600 Cr and acquisitions at ~₹600 Cr (2 ESAI, 2 aerospace), totaling ₹2,100–2,250 Cr. He stated Phase 1 and Phase 2 divestments together will fund ~80% of this, with the remainder from internal accruals or partnerships.

View source

Research and educational content only. Not investment advice.